On July 15th, Gelunhui reported that Hanshang Group (600774.SH) fell more than 8%, hitting a new 2-month low at 7.18 yuan, with a total market value of 2.12 billion yuan. The company issued a pre-reduction announcement yesterday evening, expecting that the net income for the first half of the year will be around 8 million yuan, a year-on-year decrease of about 83.41%. During the reporting period, the company's subsidiary, Chengdu Dikang Pharmaceutical Co., Ltd. was affected by factors such as group procurement and rising prices of medicinal materials, resulting in reduced profits.